MedTrace Logo

PET Study in Patients With Non-Hodgkin Lymphoma

NCT00712556 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2013-02-26

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as fluorine 18-fludeoxyglucose positron emission tomography (PET) scans, may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase I trial is studying fluorine 18-fludeoxyglucose PET scan to see how well it predicts outcomes in patients who have undergone high-dose chemotherapy and autologous stem cell transplant for non-Hodgkin lymphoma.

Conditions

Interventions

RADIATION

fluorine 18-fludeoxyglucose positron emission tomography

fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors

Sponsors & Collaborators

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Adetola A. Kassim, MD · Vanderbilt-Ingram Cancer Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00712556 on ClinicalTrials.gov